{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T10:09:47Z","timestamp":1781258987511,"version":"3.54.1"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,26]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We compared the incidence rates of hospitalized infections (HIs) between tocilizumab (TCZ) and other biological\/targeted synthetic disease-modifying antirheumatic drugs (b\/tsDMARDs) in adults aged \u226575\u2009years with rheumatoid arthritis (RA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We used a Japanese claims database from Medical Data Vision Co., Ltd (Tokyo, Japan) to perform a retrospective longitudinal population-based study in patients with RA who were prescribed b\/tsDMARDs between 2014 and 2019. We calculated adjusted risk ratios (aRRs) for HIs in three age groups (&amp;lt;65, \u226565 and &amp;lt;75, and \u226575\u2009years).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 5506 patients, 2265 (41.1%) were &amp;lt;65\u2009years, 1709 (31.0%) were 65\u201374 years, and 1532 (27.8%) were \u226575 years. Crude incidence rates (\/100 person-years) of HIs were 3.99, 7.27, and 10.77, respectively. In the oldest group, aRRs (95% confidence interval) for HIs (b\/tsDMARDs versus TCZ) were as follows: etanercept, 2.40 (1.24\u20134.61); adalimumab, 1.90 (0.75\u20134.83); golimumab, 1.21 (0.66\u20132.23); and abatacept, 0.89 (0.49\u20131.62). In the other age groups, the noticeable difference was a lower aRR of etanercept versus TCZ in the youngest group (0.30, 0.11\u20130.85).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In patients with RA aged \u226575\u2009years, b\/tsDMARDs have a similar risk of HIs to tocilizumab except for etanercept.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/road031","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T14:00:05Z","timestamp":1681221605000},"page":"287-296","source":"Crossref","is-referenced-by-count":10,"title":["Risk of hospitalized infections in older elderly patients with rheumatoid arthritis treated with tocilizumab or other biological\/targeted synthetic disease-modifying antirheumatic drugs: Evaluation of data from a Japanese claims database"],"prefix":"10.1093","volume":"34","author":[{"given":"Masayoshi","family":"Harigai","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Wakayama Medical University , Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Public Health and Epidemiology, Meiji Pharmaceutical University , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ataru","family":"Igarashi","sequence":"additional","affiliation":[{"name":"Department of Health Economics & Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo , Tokyo, Japan"},{"name":"Unit of Public Health and Preventive Medicine, Yokohama City University of Medicine , Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Shoji","sequence":"additional","affiliation":[{"name":"Medilead Inc., Tokyo Opera City Tower , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Medilead Inc., Tokyo Opera City Tower , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"Medilead Inc., Tokyo Opera City Tower , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misako","family":"Makishima","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amika","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Okada","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhisa","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Kawahito","sequence":"additional","affiliation":[{"name":"Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,17]]},"reference":[{"key":"2024022623083931400_R1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/14397595.2013.854059","article-title":"Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I)","volume":"24","author":"Yamanaka","year":"2014","journal-title":"Mod Rheumatol"},{"key":"2024022623083931400_R2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/s10165-012-0702-1","article-title":"Management of rheumatoid arthritis: the 2012 perspective","volume":"23","author":"Yamanaka","year":"2013","journal-title":"Mod Rheumatol"},{"key":"2024022623083931400_R3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2019.1660028","article-title":"A large observational cohort study of rheumatoid arthritis, IORRA: providing context for today\u2019s treatment options","volume":"30","author":"Yamanaka","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2024022623083931400_R4","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/1756-185X.13974","article-title":"Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan","volume":"23","author":"Nakajima","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"2024022623083931400_R5","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/1756-185X.12998","article-title":"The age at onset of rheumatoid arthritis is increasing in Japan: a nationwide database study","volume":"20","author":"Kato","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"2024022623083931400_R6","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/ggi.13118","article-title":"Redefining the elderly as aged 75 years and older: proposal from the Joint Committee of Japan Gerontological Society and the Japan Geriatrics Society","volume":"17","author":"Ouchi","year":"2017","journal-title":"Geriatr Gerontol Int"},{"key":"2024022623083931400_R7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40266-015-0341-2","article-title":"Targeting low disease activity in elderly-onset rheumatoid arthritis: current and future roles of biological disease-modifying antirheumatic drugs","volume":"33","author":"Sugihara","year":"2016","journal-title":"Drugs Aging"},{"key":"2024022623083931400_R8","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s40265-020-01349-1","article-title":"Selectivity of Janus kinase inhibitors in rheumatoid arthritis and other immune-mediated inflammatory diseases: is expectation the root of all headache?","volume":"80","author":"Harigai","year":"2020","journal-title":"Drugs"},{"key":"2024022623083931400_R9","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3109\/s10165-011-0541-5","article-title":"Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients","volume":"22","author":"Koike","year":"2012","journal-title":"Mod Rheumatol"},{"key":"2024022623083931400_R10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3899\/jrheum.130466","article-title":"Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan","volume":"41","author":"Koike","year":"2014","journal-title":"J Rheumatol"},{"key":"2024022623083931400_R11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40744-018-0101-y","article-title":"Safety, effectiveness, and treatment persistence of golimumab in elderly patients with rheumatoid arthritis in real-world clinical practice in Japan","volume":"5","author":"Okazaki","year":"2018","journal-title":"Rheumatol Ther"},{"key":"2024022623083931400_R12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard.2007.072967","article-title":"Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis","volume":"67","author":"Takeuchi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2024022623083931400_R13","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3109\/14397595.2015.1123211","article-title":"Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis","volume":"26","author":"Harigai","year":"2016","journal-title":"Mod Rheumatol"},{"key":"2024022623083931400_R14","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3109\/14397595.2015.1106682","article-title":"High prevalence of cardiovascular comorbidities in patients with rheumatoid arthritis from a population-based cross-sectional study of a Japanese health insurance database","volume":"26","author":"Sakai","year":"2016","journal-title":"Mod Rheumatol"},{"key":"2024022623083931400_R15","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1111\/1756-185X.13300","article-title":"No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database","volume":"21","author":"Sakai","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"2024022623083931400_R16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-022-02807-9","article-title":"Unincreased risk of hospitalized infection under targeted therapies versus methotrexate in elderly patients with rheumatoid arthritis: a retrospective cohort study","volume":"24","author":"Sakai","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2024022623083931400_R17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3820\/jjpe.21.23","article-title":"Utilization of MDV data and data quality control","volume":"21","author":"Nakamura","year":"2016","journal-title":"Japanese J Pharmacoepidemiol"},{"key":"2024022623083931400_R18","first-page":"939","article-title":"Guidelines for the management of rheumatoid arthritis","volume":"74","author":"Kawahito","year":"2016","journal-title":"Nihon Rinsho"},{"key":"2024022623083931400_R19","doi-asserted-by":"crossref","DOI":"10.1186\/s40064-016-2800-6","article-title":"Risk for cardiovascular disease in Japanese patients with rheumatoid arthritis: a large-scale epidemiological study using a healthcare database","volume":"5","author":"Tanaka","year":"2016","journal-title":"Springerplus"},{"key":"2024022623083931400_R20","doi-asserted-by":"crossref","DOI":"10.1186\/s12891-021-04259-9","article-title":"The validity of the claims-based definition of rheumatoid arthritis evaluated in 64 hospitals in Japan","volume":"22","author":"Kubota","year":"2021","journal-title":"BMC Musculoskelet Disord"},{"key":"2024022623083931400_R21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/art.39399","article-title":"Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in Medicare","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2024022623083931400_R22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.37737\/ace.22004","article-title":"Validation study of algorithms to identify malignant tumors and serious infections in a Japanese administrative healthcare database","volume":"4","author":"Nishikawa","year":"2022","journal-title":"Ann Clin Epidemiol"},{"key":"2024022623083931400_R23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179179","article-title":"Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: a multicenter retrospective cohort study in Japan","volume":"12","author":"Mori","year":"2017","journal-title":"PLoS One"},{"key":"2024022623083931400_R24","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/6730812","article-title":"Incidence and risk factors for infections requiring hospitalization, including pneumocystis pneumonia, in Japanese patients with rheumatoid arthritis","volume":"2017","author":"Hashimoto","year":"2017","journal-title":"Int J Rheumatol"},{"key":"2024022623083931400_R25","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/annrheumdis-2020-218992","article-title":"Age-based (&lt;65 vs \u226565 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry","volume":"80","author":"Winthrop","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024022623083931400_R26","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1136\/annrheumdis-2019-216852","article-title":"Infections in baricitinib clinical trials for patients with active rheumatoid arthritis","volume":"79","author":"Winthrop","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024022623083931400_R27","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/annrheumdis-2018-214367","article-title":"Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study","volume":"78","author":"Pawar","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2024022623083931400_R28","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3899\/jrheum.141210","article-title":"Long-term safety of tocilizumab: results from 3 years of follow-up postmarketing surveillance of 5573 patients with rheumatoid arthritis in Japan","volume":"42","author":"Yamamoto","year":"2015","journal-title":"J Rheumatol"},{"key":"2024022623083931400_R29","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","article-title":"Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"2024022623083931400_R30","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3899\/jrheum.190260","article-title":"Real-world safety of adalimumab in rheumatoid arthritis: analysis of a prospective US-based registry","volume":"47","author":"Harrold","year":"2020","journal-title":"J Rheumatol"},{"key":"2024022623083931400_R31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/mr\/roac017","article-title":"Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication","volume":"33","author":"Kawahito","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2024022623083931400_R32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40801-022-00296-5","article-title":"Context and considerations for use of two Japanese real-world databases in Japan: Medical Data Vision and Japanese Medical Data Center","volume":"9","author":"Laurent","year":"2022","journal-title":"Drugs Real World Outcomes"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/road031\/50449029\/road031.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/2\/287\/56760763\/road031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/2\/287\/56760763\/road031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T23:09:14Z","timestamp":1708988954000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/34\/2\/287\/7113718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,17]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,3,17]]},"published-print":{"date-parts":[[2024,2,26]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/road031","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3,1]]},"published":{"date-parts":[[2023,3,17]]}}}